Photobiomodulation at therapeutic wavelengths supports mitochondrial function, reduces inflammation, and may assist with body composition changes when used alongside a structured program
Any new or worsening neurological symptoms warrant thorough clinical evaluation to distinguish between medication effects, disease progression, or unrelated conditions
In 2019, nearly 90% of patients initiating therapy were diabetics, but by 2023, their share had dropped to just over 70%
[1] [2] B12 functions as a cofactor in cellular metabolism, participating in the conversion of homocysteine to methionine and the metabolism of methylmalonic acid, both crucial for energy production
In those on maximal dose of a GLP-1 RA (either subcutaneous or oral), I would initiate tirzepatide at the 5 mg weekly dose
What is the indication for Zepbound (tirzepatide) in a patient with a Body Mass Index (BMI) of 28, hypercholesterolemia, and pre-diabetes mellitus (pre-DM)?